about
Bortezomib primes neuroblastoma cells for TRAIL-induced apoptosis by linking the death receptor to the mitochondrial pathwayAmplification and overexpression of the IGF2 regulator PLAG1 in hepatoblastomaElevated expression of Wnt antagonists is a common event in hepatoblastomasCombined Scintigraphy and Tumor Marker Analysis Predicts Unfavorable Histopathology of Neuroblastic Tumors with High AccuracyThe Children's Hepatic tumors International Collaboration (CHIC): Novel global rare tumor database yields new prognostic factors in hepatoblastoma and becomes a research modelMicroRNA-492 is processed from the keratin 19 gene and up-regulated in metastatic hepatoblastoma.Should children at risk for familial adenomatous polyposis be screened for hepatoblastoma and children with apparently sporadic hepatoblastoma be screened for APC germline mutations?Selective methylation of CpGs at regulatory binding sites controls NNAT expression in Wilms tumors.Hepatocyte growth factor induces cell scattering through MAPK/Egr-1-mediated upregulation of Snail.Where do we stand with hepatoblastoma? A review.Neonatal liver tumours.IGFBP3 impedes aggressive growth of pediatric liver cancer and is epigenetically silenced in vascular invasive and metastatic tumorsTreatment and outcome of Ganglioneuroma and Ganglioneuroblastoma intermixed.Surgical treatment of hepatoblastoma in children.Management of liver tumors in childhood.Mesoblastic nephroma--a report from the Gesellschaft fur Pädiatrische Onkologie und Hämatologie (GPOH).Review of image defined risk factors in localized neuroblastoma patients: Results of the GPOH NB97 trial.Treatment of hepatoblastoma in the German cooperative pediatric liver tumor studies.A better way forward: targeting hedgehog signaling in liver cancer.Hepatoblastoma: recent developments in research and treatment.Stem-like cells in human hepatoblastoma.Current Management of Fetal and Neonatal Renal Tumors.Targeting the Neurokinin-1 Receptor Compromises Canonical Wnt Signaling in Hepatoblastoma.Small cell undifferentiated (SCUD) hepatoblastomas: All malignant rhabdoid tumors?Pediatric hepatocellular carcinoma: challenges and solutions.Epigallocatechin-3-gallate inhibits hepatoblastoma growth by reactivating the Wnt inhibitor SFRP1.Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children's Hepatic tumors International Collaboration.Parents reported reduced symptoms and improved satisfaction after fundoplication and their perceptions were an important outcome measure.Outcomes for patients with congenital hepatoblastoma.Rapamycin blocks hepatoblastoma growth in vitro and in vivo implicating new treatment options in high-risk patients.Activation of phosphatidylinositol-3'-kinase/AKT signaling is essential in hepatoblastoma survival.Self-administered procedural analgesia using nitrous oxide/oxygen (50:50) in the pediatric surgery emergency room: effectiveness and limitations.Low expression of N-myc downstream-regulated gene 2 (NDRG2) correlates with poor prognosis in hepatoblastoma.Laparoscopic fluorescence diagnosis of peritoneal metastases from human hepatoblastoma in nude rats.Subcutaneous and intrahepatic growth of human hepatoblastoma in immunodeficient mice.Mutations and elevated transcriptional activity of conductin (AXIN2) in hepatoblastomas.Complete surgical resection improves outcome in INRG high-risk patients with localized neuroblastoma older than 18 months.Connectivity map identifies HDAC inhibition as a treatment option of high-risk hepatoblastomaThe International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report.Prognostic impact of molecular genetic alterations in hepatoblastoma.
P50
Q24298796-AB7D7EEF-65C7-47F8-B120-FC8845ED41D3Q28236163-D6B239E6-14BD-4B34-B7E3-68DCB179A148Q28256831-DFACDFDA-744F-491B-9E8A-1C82DFB1E84EQ28546522-9C711578-7D84-4B6E-ACB5-499DE78EC3A9Q28589033-05896F9F-EF41-4119-9BA8-E94E3A813739Q34164408-A0299852-A670-422C-AF33-15D45950DAD1Q34562989-5F4D1A49-9E35-4155-91C8-188EA185D6E9Q34795049-874B1558-8F0C-4E19-A165-580208DBDFD8Q34972866-8A17D0DE-77C4-4F9B-BFED-EA834537F738Q35196714-8CC52E7D-C20A-4B67-82F0-DBB28F584FA5Q35682630-25095FF8-0076-4CA3-9034-C34C0309BCEDQ35951090-B467908E-6AC8-41EF-98FD-F694FE109119Q36087775-61C20943-3874-48ED-893D-3CA425E7DAC3Q36365158-7A812353-5A12-49CF-9A04-29A99F8613CAQ36387105-CDC95099-C656-4CB4-BC3D-6767E6184FC8Q36441147-ED28F303-57C2-454E-B006-D71A883068E4Q36960028-5418E3C4-DED3-40A5-9FA2-055416132468Q37971636-5C852FE1-FE90-4043-8B7E-9C7C0AAB76F0Q37971750-5A9366A3-5585-488A-8CE8-941DCFA1D609Q37976204-DA47F9AD-371B-49E0-AEAB-23417E883883Q38324022-BA9FA34C-BED2-41E0-A1B2-5FC4D9741613Q38546175-C118A7BD-AB9D-43EF-9C3B-3872CA2CA3A1Q38823717-D9F790F4-D502-4058-B7CE-26453C747339Q38880725-D100A80D-7352-4127-AA6A-A66005ADDC87Q38987929-B0ACC79B-BF64-48AC-8525-6D3556D209B5Q39078216-08D00E18-9E58-41F4-8D9F-CF7C3508C392Q39155861-C9BE8A59-87B2-40DA-BACA-1C11773A4467Q39302493-F722BEC5-C2F2-4695-924C-C5378FE8B154Q39396991-E25809B2-081F-43E4-B0EC-5A25E918A397Q39405128-86EF4FB2-0CA1-425B-BAC0-15EC3B29F5B1Q39827938-75FC46BE-1E83-4336-9984-75163644F094Q40190587-D27DAC11-29E6-4EE4-9AF8-8CA06D823409Q40232656-76766AC8-2256-4C02-AAC3-248DADDC9AD7Q40252058-00954884-838F-4123-935C-712460E1F7D6Q40266452-A5AB9C02-BFDE-4EDF-A0B9-E12E68D93649Q40493289-20BB4662-E6B5-4B44-B1D0-315D8BDC18CFQ41250708-E5E81873-5E6E-4D1D-85B7-0B4B7B0A2E9FQ41728555-D722B288-E01D-4A64-B9E8-9FB2BDEFCFD1Q43170089-96D640EA-F91C-4715-AB49-006405869D09Q43867821-0A40B5CD-2577-4199-8A53-08C72E349C46
P50
description
onderzoeker
@nl
name
Dietrich von Schweinitz
@ast
Dietrich von Schweinitz
@en
Dietrich von Schweinitz
@es
Dietrich von Schweinitz
@nl
Dietrich von Schweinitz
@sl
type
label
Dietrich von Schweinitz
@ast
Dietrich von Schweinitz
@en
Dietrich von Schweinitz
@es
Dietrich von Schweinitz
@nl
Dietrich von Schweinitz
@sl
prefLabel
Dietrich von Schweinitz
@ast
Dietrich von Schweinitz
@en
Dietrich von Schweinitz
@es
Dietrich von Schweinitz
@nl
Dietrich von Schweinitz
@sl
P106
P21
P31
P569
2000-01-01T00:00:00Z